CORDIS
EU research results

CORDIS

English EN
The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use

The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use

Objective

Antimicrobial resistance (AMR) is of great public health concern, causing numerous losses of lives worldwide and threatening to reverse many of the considerable strides modern medicine has made over the last century. There is a need to stratify antibiotic and alternative treatments in terms of the actual benefit for the patient, improving patient outcome and limit the impact on AMR. High quality, effective and appropriate diagnostic tests to steer appropriate use of antibiotics are available. However, implementation of these tests into daily healthcare practice is hampered due to lack of insight in the medical, technological and health economical value and limited knowledge about psychosocial, ethical, regulatory and organisational barriers to their implementation into clinical practice.

VALUE-Dx will define and understand these value indicators and barriers to adoption of diagnostics of Community-Acquired Acute Respiratory Tract Infections (CA-ARTI) in order to develop and improve health economic models to generate insight in the whole value of diagnostics and develop policy and regulatory recommendations. In addition, efficient clinical algorithms and user requirement specifications of tests will be developed fuelling the medical and technological value of CA-ARTI diagnostics. The value of diagnostics will be tested and demonstrated in a unique pan-European clinical and laboratory research infrastructure allowing for innovative adaptive trial designs to evaluate novel CA-ARTI diagnostics. Close and continuous interaction with the VALUE-Dx multi-stakeholder platform provides for optimal alignment of VALUE-Dx activities with stakeholder opinions, expert knowledge and interests.

A variety of dissemination and advocacy measures will promote wide-spread adoption of clinical and cost-effective innovative diagnostics to achieve more personalized, evidence-based antibiotic prescription in order to transform clinical practice, improve patient outcomes and combat AMR.

Coordinator

UNIVERSITEIT ANTWERPEN

Address

Prinsstraat 13
2000 Antwerpen

Belgium

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 2 282 957

Participants (25)

Sort alphabetically

Sort by EU Contribution

Expand all

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

United Kingdom

EU Contribution

€ 1 716 160

UNIVERSITAIR MEDISCH CENTRUM UTRECHT

Netherlands

EU Contribution

€ 730 458

FONDAZIONE PENTA-FOR THE TREATMENT AND CARE OF CHILDREN WITH HIV-ONLUS

Italy

EU Contribution

€ 189 444

UNIVERSITA DEGLI STUDI DI VERONA

Italy

EU Contribution

€ 275 409

THE UNIVERSITY OF EDINBURGH

United Kingdom

EU Contribution

€ 75 765

ACADEMISCH ZIEKENHUIS GRONINGEN

Netherlands

EU Contribution

€ 305 596

THE HEALTH CORPORATION - RAMBAM

Israel

EU Contribution

€ 226 444

UNIVERSIDAD DE LA RIOJA

Spain

EU Contribution

€ 136 693

THE TRUSTEES OF BOSTON UNIVERSITY

United States

EU Contribution

€ 15 641

BIOASTER FONDATION DE COOPERATION SCIENTIFIQUE

France

EU Contribution

€ 66 337

FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS

Switzerland

EU Contribution

€ 77 858

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

United Kingdom

EU Contribution

€ 137 793

GESUNDHEIT OSTERREICH GMBH

Austria

EU Contribution

€ 88 520

EUROPEAN SOCIETY CLINICAL MICROBIOLOGY INFECTIOUS DISEASES (EUROPAISCHE GESELLSCHAFT FUR KLINISCHE MIKROBIOLOGIE INFEKTIONSKRANKHEITEN)

Switzerland

EU Contribution

€ 184 649

EUROPEAN RESPIRATORY SOCIETY

Switzerland

EU Contribution

€ 144 902

BERRY CONSULTANTS LLP

United Kingdom

EU Contribution

€ 72 411

LUXEMBOURG INSTITUTE OF HEALTH

Luxembourg

EU Contribution

€ 37 365

ZORGONDERZOEK NEDERLAND ZON

Netherlands

EU Contribution

€ 34 698

BIOMERIEUX SA

France

JANSSEN PHARMACEUTICA NV

Belgium

ACCELERATE DIAGNOSTICS SL

Spain

ALERE INTERNATIONAL LIMITED

Ireland

BIO-RAD

France

BD SWITZERLAND SARL

Switzerland

THE WELLCOME TRUST LIMITED

United Kingdom

Project information

Grant agreement ID: 820755

Status

Ongoing project

  • Start date

    1 April 2019

  • End date

    31 March 2023

Funded under:

H2020-EU.3.1.7.

  • Overall budget:

    € 13 739 927,20

  • EU contribution

    € 6 799 100

Coordinated by:

UNIVERSITEIT ANTWERPEN

Belgium